Ostra białaczka promielocytowa (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ostra białaczka promielocytowa" in Polish language version.

refsWebsite

Global rank Polish rank

18nih.gov

4^th place

7^th place

8doi.org

2^nd place

6^th place

4ashpublications.org

low place

8,449^th place

1nature.com

234^th place

204^th place

1ni.ac.rs

low place

1hematologylibrary.org

low place

ashpublications.org

MA. Sanz, D. Grimwade, MS. Tallman, B. Lowenberg i inni. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. „Blood”. 113 (9), s. 1875-91, Feb 2009. DOI: 10.1182/blood-2008-04-150250. PMID: 18812465.
ZY. Wang, Z. Chen. Acute promyelocytic leukemia: from highly fatal to highly curable. „Blood”. 111 (5), s. 2505-15, Mar 2008. DOI: 10.1182/blood-2007-07-102798. PMID: 18299451.
GQ. Chen, XG. Shi, W. Tang, SM. Xiong i inni. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. „Blood”. 89 (9), s. 3345-53, May 1997. PMID: 9129041.
ZX. Shen, GQ. Chen, JH. Ni, XS. Li i inni. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. „Blood”. 89 (9), s. 3354-60, May 1997. PMID: 9129042.

doi.org

Tallman MS. What is the role of arsenic in newly diagnosed APL?. „Best practice & research. Clinical haematology”. 4 (21), s. 659–66, grudzień 2008. DOI: 10.1016/j.beha.2008.09.002. PMID: 19041605.
SJ. Shah, S. Blumen, I. Pitha-Rowe, S. Kitareewan i inni. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. „Mol Cancer Ther”. 7 (4), s. 905-14, Apr 2008. DOI: 10.1158/1535-7163.MCT-07-0515. PMID: 18413804.
MA. Sanz, D. Grimwade, MS. Tallman, B. Lowenberg i inni. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. „Blood”. 113 (9), s. 1875-91, Feb 2009. DOI: 10.1182/blood-2008-04-150250. PMID: 18812465.
Y. Chen, H. Kantarjian, H. Wang, J. Cortes i inni. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. „Cancer”. 118 (23), s. 5811-8, Dec 2012. DOI: 10.1002/cncr.27623. PMID: 22707337.
Ivan Petković, Ivica Pejčić, Svetislav Vrbić. New frontiers of target therapy in oncology: acute promyelocytic leukemia. „Acta facultatis medicae naissensis”, 2014. DOI: 10.2478/afmnai-2014-0002. [dostęp 2015-04-24].
RC. Ribeiro, E. Rego. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. „Hematology Am Soc Hematol Educ Program”, s. 162-8, 2006. DOI: 10.1182/asheducation-2006.1.162. PMID: 17124056.
Tallman MS., Altman JK. Curative strategies in acute promyelocytic leukemia.. „Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program”, s. 391–9, 2008. DOI: 10.1182/asheducation-2008.1.391. PMID: 19074116.
ZY. Wang, Z. Chen. Acute promyelocytic leukemia: from highly fatal to highly curable. „Blood”. 111 (5), s. 2505-15, Mar 2008. DOI: 10.1182/blood-2007-07-102798. PMID: 18299451.

hematologylibrary.org

asheducationbook.hematologylibrary.org

RC. Ribeiro, E. Rego. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. „Hematology Am Soc Hematol Educ Program”, s. 162-8, 2006. DOI: 10.1182/asheducation-2006.1.162. PMID: 17124056.

nature.com

M. Vickers, G. Jackson, P. Taylor. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. „Leukemia”. 14 (4), s. 722-6, Apr 2000. PMID: 10764161.

ni.ac.rs

medfak.ni.ac.rs

Ivan Petković, Ivica Pejčić, Svetislav Vrbić. New frontiers of target therapy in oncology: acute promyelocytic leukemia. „Acta facultatis medicae naissensis”, 2014. DOI: 10.2478/afmnai-2014-0002. [dostęp 2015-04-24].

nih.gov

ncbi.nlm.nih.gov

Tallman MS. What is the role of arsenic in newly diagnosed APL?. „Best practice & research. Clinical haematology”. 4 (21), s. 659–66, grudzień 2008. DOI: 10.1016/j.beha.2008.09.002. PMID: 19041605.
M. Vickers, G. Jackson, P. Taylor. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. „Leukemia”. 14 (4), s. 722-6, Apr 2000. PMID: 10764161.
YH. Xiao, WH. Miller, RP. Warrell, E. Dmitrovsky i inni. Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. „Am J Pathol”. 143 (5), s. 1301-11, Nov 1993. PMID: 8238249.
SJ. Shah, S. Blumen, I. Pitha-Rowe, S. Kitareewan i inni. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. „Mol Cancer Ther”. 7 (4), s. 905-14, Apr 2008. DOI: 10.1158/1535-7163.MCT-07-0515. PMID: 18413804.
JV. Raelson, C. Nervi, A. Rosenauer, L. Benedetti i inni. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. „Blood”. 88 (8), s. 2826-32, Oct 1996. PMID: 8874178.
MA. Sanz, D. Grimwade, MS. Tallman, B. Lowenberg i inni. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. „Blood”. 113 (9), s. 1875-91, Feb 2009. DOI: 10.1182/blood-2008-04-150250. PMID: 18812465.
Y. Chen, H. Kantarjian, H. Wang, J. Cortes i inni. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. „Cancer”. 118 (23), s. 5811-8, Dec 2012. DOI: 10.1002/cncr.27623. PMID: 22707337.
RC. Ribeiro, E. Rego. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. „Hematology Am Soc Hematol Educ Program”, s. 162-8, 2006. DOI: 10.1182/asheducation-2006.1.162. PMID: 17124056.
Tallman MS., Altman JK. Curative strategies in acute promyelocytic leukemia.. „Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program”, s. 391–9, 2008. DOI: 10.1182/asheducation-2008.1.391. PMID: 19074116.
RL. Reddick, JC. Costa, SJ. Marx. Parathyroid hyperplasia and parathyromatosis. „Lancet”. 1 (8010), s. 549, Mar 1977. PMID: 65648.
J. Bernard, M. Weil, M. Boiron, C. Jacquillat i inni. Acute promyelocytic leukemia: results of treatment by daunorubicin. „Blood”. 41 (4), s. 489-96, Apr 1973. PMID: 4510926.
ZY. Wang, Z. Chen. Acute promyelocytic leukemia: from highly fatal to highly curable. „Blood”. 111 (5), s. 2505-15, Mar 2008. DOI: 10.1182/blood-2007-07-102798. PMID: 18299451.
ME. Huang, YC. Ye, SR. Chen, JC. Zhao i inni. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. „Chin Med J (Engl)”. 100 (12), s. 949-53, Dec 1987. PMID: 3133168.
ME. Huang, YC. Ye, SR. Chen, JR. Chai i inni. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. „Blood”. 72 (2), s. 567-72, Aug 1988. PMID: 3165295.
L. Degos, C. Chomienne, MT. Daniel, R. Berger i inni. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. „Lancet”. 336 (8728), s. 1440-1, Dec 1990. PMID: 1978887.
S. Castaigne, C. Chomienne, MT. Daniel, P. Ballerini i inni. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. „Blood”. 76 (9), s. 1704-9, Nov 1990. PMID: 2224119.
GQ. Chen, XG. Shi, W. Tang, SM. Xiong i inni. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. „Blood”. 89 (9), s. 3345-53, May 1997. PMID: 9129041.
ZX. Shen, GQ. Chen, JH. Ni, XS. Li i inni. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. „Blood”. 89 (9), s. 3354-60, May 1997. PMID: 9129042.